Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

. 2023 Oct ; 37 (10) : 2129-2132. [epub] 20230826

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid37634011
E-zdroje Online Plný text
Odkazy

PubMed 37634011
PubMed Central PMC10539163
DOI 10.1038/s41375-023-02008-6
PII: 10.1038/s41375-023-02008-6
Knihovny.cz E-zdroje

Zobrazit více v PubMed

Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10:359–71. doi: 10.2147/JBM.S189922. PubMed DOI PMC

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81. doi: 10.1038/leu.2013.163. PubMed DOI PMC

Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569–72. doi: 10.1038/s41375-021-01447-3. PubMed DOI

Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592–601. doi: 10.1038/s41375-021-01183-8. PubMed DOI PMC

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–208. doi: 10.1016/S2352-3026(19)30236-4. PubMed DOI

Kiladjian J-J, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36:1408–11. doi: 10.1038/s41375-022-01528-x. PubMed DOI PMC

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–33. doi: 10.1182/blood-2008-09-176818. PubMed DOI

Crisà E, Cerrano M, Beggiato E, Benevolo G, Lanzarone G, Manzini PM, et al. Can pegylated interferon improve the outcome of polycythemia vera patients? J Hematol Oncol. 2017;10:15. doi: 10.1186/s13045-017-0395-1. PubMed DOI PMC

Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934–42. PubMed PMC

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574–9. doi: 10.1038/leu.2010.148. PubMed DOI

Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199. doi: 10.1038/s41408-021-00581-6. PubMed DOI PMC

Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O’Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135:1696–703. doi: 10.1182/blood.2019003347. PubMed DOI PMC

Najít záznam

Citační ukazatele

Možnosti archivace